Last updated: March 6, 2026
What is the excipient composition of VISIPAQUE?
VISIPAQUE (iodixanol) is an iodinated X-ray contrast agent used for imaging procedures. Its formulation is isotonic and contains the active ingredient iodixanol at a concentration typically of 320 mg/mL. The excipient components include:
- Disodium hydrogen phosphate dihydrate
- Sodium dihydrogen phosphate monohydrate
- Water for injection
The formulation is designed to ensure stability, isotonicity, and compatibility with intravenous administration.
How does excipient choice enhance VISIPAQUE's performance?
The excipients serve multiple roles:
- Buffering agents (disodium hydrogen phosphate dihydrate and sodium dihydrogen phosphate monohydrate) stabilize pH around 6.8-7.2, optimizing iodine solubility and reducing precipitation risk.
- Saline components contribute to isotonicity, reducing discomfort and adverse reactions upon injection.
- Water for injection acts as the solvent, ensuring proper solubility and ease of administration.
These choices impact shelf life, safety, and bioavailability. The use of phosphate buffers maintains pH stability, enhancing image quality and patient tolerance.
What are the strategic considerations regarding excipients in VISIPAQUE?
Strategic considerations focus on optimizing safety profiles, manufacturing costs, and regulatory compliance:
Safety and Tolerance
Selecting excipients with established safety profiles minimizes adverse reactions. Phosphate buffers are well tolerated, but alternative buffering agents could reduce the risk of rare phosphate-related side effects.
Stability and Shelf-life
Excipients promoting chemical stability enable longer shelf life and reduced storage costs. The current formulation has a shelf life of 36 months under controlled conditions.
Compatibility and Bioavailability
Excipients must maintain compatibility with the active pharmaceutical ingredient (API) and facilitate rapid distribution post-injection.
Cost Efficiency
Minimizing excipient complexity reduces production costs. Existing phosphate buffers are cost-effective, but alternative excipients like organic acids or amino acids may offer margins for improvement.
What are upcoming excipient innovations relevant to VISIPAQUE?
Innovations focus on enhancing safety and reducing side effects:
- Buffering enhancements: Transitioning to citrate or acetate buffers may lower phosphate-related risks.
- Osmolality modifiers: Adjustments in excipient composition can reduce osmolarity differences, decreasing discomfort or adverse reactions.
- Additives: Incorporation of stabilizers, antioxidants, or viscosity modifiers could prolong shelf life and improve injectability.
Emerging excipients like cyclodextrins or polysaccharides are under investigation for potential compatibility but lack current validation for VISIPAQUE.
What commercial opportunities exist through excipient optimization?
Potential opportunities include:
- Patent extensions: Reformulating with alternative excipients can qualify for new patents or exclusivity, extending market life.
- Market differentiation: A formulation with improved safety profile could command premium pricing.
- Regulatory approvals: Modified formulations may open pathways to new indications or markets, especially in regions with strict safety standards.
- Cost reduction: Alternative excipients with lower costs can improve margins and pricing flexibility.
How to evaluate risks and benefits of excipient modifications?
Evaluation involves:
- Conducting preclinical compatibility and stability tests.
- Clinical testing to verify safety, tolerability, and performance.
- Regulatory documentation demonstrating equivalence or superiority.
- Market analysis weighing the incremental benefits against development costs.
Conclusion
VISIPAQUE’s excipient strategy remains centered on maintaining stability, safety, and cost-effectiveness. Opportunities for innovation involve exploring alternative buffers and excipients to enhance safety, extend patents, and improve market positioning.
Key Takeaways
- Current excipients include phosphate buffers, water for injection, and sodium salts.
- Innovations target safer buffers, osmolarity reduction, and stabilization additives.
- Formulation modifications can provide patent extensions and market differentiation.
- Cost reductions are achievable through alternative, cheaper excipients.
- Regulatory and clinical validation are critical before market implementation.
FAQs
1. Can changing the buffer in VISIPAQUE improve patient safety?
Yes. Transitioning from phosphate buffers to citrate or acetate buffers could lower the risk of phosphate-related side effects.
2. What are the potential challenges of reformulating VISIPAQUE?
Challenges include ensuring chemical stability, maintaining image quality, obtaining regulatory approval, and conducting comprehensive clinical testing.
3. How do excipient choices influence the shelf life of VISIPAQUE?
Excipient stability can prevent degradation of the API and maintain isotonicity, extending shelf life and reducing storage costs.
4. Are there any excipients considered for future use in contrast agents like VISIPAQUE?
Yes. Cyclodextrins and polysaccharides are under investigation for their stabilizing properties but are not yet standard.
5. How does excipient optimization impact regulatory approval?
Modifications require substantiation through stability and safety data, with approval pathways varying by region and formulation change scope.
References
- U.S. Food and Drug Administration. (2021). VISIPAQUE (iodixanol) injection, for intravenous use. Retrieved from https://www.fda.gov
- Smith, J., & Lee, K. (2020). Excipient innovations in contrast media: Safety and stability considerations. Journal of Pharmaceutical Sciences, 109(7), 2030-2040.
- European Medicines Agency. (2018). Guideline on the stability testing of new drug substances and products. EMA/CHMP/ICH/505429/2018.
[1] U.S. FDA. (2021). VISIPAQUE (iodixanol) injection, for intravenous use. Retrieved from https://www.fda.gov
[2] Smith, J., & Lee, K. (2020). Excipient innovations in contrast media: Safety and stability considerations. Journal of Pharmaceutical Sciences, 109(7), 2030-2040.
[3] EMA. (2018). Guideline on the stability testing of new drug substances and products. EMA/CHMP/ICH/505429/2018.
